Humoral Responses Elicited after a Fifth Dose of SARS-CoV-2 mRNA Bivalent Vaccine
Alexandra Tauzin,
Guillaume Beaudoin-Bussières,
Mehdi Benlarbi,
Manon Nayrac,
Yuxia Bo,
Gabrielle Gendron-Lepage,
Halima Medjahed,
Josée Perreault,
Laurie Gokool,
Pascale Arlotto,
Chantal Morrisseau,
Cécile Tremblay,
Daniel E. Kaufmann,
Valérie Martel-Laferrière,
Inès Levade,
Marceline Côté,
Renée Bazin,
Andrés Finzi
Affiliations
Alexandra Tauzin
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Guillaume Beaudoin-Bussières
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Mehdi Benlarbi
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Manon Nayrac
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Yuxia Bo
Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Gabrielle Gendron-Lepage
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Halima Medjahed
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Josée Perreault
Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada
Laurie Gokool
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Pascale Arlotto
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Chantal Morrisseau
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Cécile Tremblay
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Daniel E. Kaufmann
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Valérie Martel-Laferrière
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
Inès Levade
Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada
Marceline Côté
Department of Biochemistry, Microbiology and Immunology, and Centre for Infection, Immunity and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada
Renée Bazin
Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada
Andrés Finzi
Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada
While an important part of the world’s population is vaccinated against SARS-CoV-2, new variants continue to emerge. We observe that even after a fifth dose of the mRNA bivalent vaccine, most vaccinated individuals have antibodies that poorly neutralize several Omicron subvariants, including BQ.1.1, XBB, XBB.1.5, FD.1.1, and CH.1.1. However, Fc-effector functions remain strong and stable over time against new variants, which may partially explain why vaccines continue to be effective. We also observe that donors who have been recently infected have stronger antibody functional activities, including neutralization and Fc-effector functions, supporting the observations that hybrid immunity leads to better humoral responses.
